Warfarin

Evidence Level: L4

Predicted Indications: 7

Warfarin
Warfarin: From Thrombotic Disease to Heparin Cofactor 2 Deficiency

## Pharmacist Assessment Report

Warfarin: From Thrombotic Disease to Heparin Cofactor 2 Deficiency

One-Sentence Summary

Warfarin is a vitamin K antagonist anticoagulant, originally used for pulmonary embolism, thrombotic disease and intracranial embolism. The TxGNN model predicts it may be effective for heparin cofactor 2 deficiency, but the support is thin: 0 clinical trials and 3 publications, all case or family reports. This is essentially an extension of warfarin's existing use in thrombosis, not a new therapeutic concept.

Quick Overview

Item	Content
Original Indication	Pulmonary embolism, thrombotic disease, intracranial embolism (from the knowledge graph; no approved indication text is available for the New Zealand licences)
Predicted New Indication	Heparin cofactor 2 deficiency
TxGNN Prediction Score	99.87%
Evidence Level	L4
New Zealand Market Status	Cancelled only (all licences cancelled)
Number of Authorizations	6 (0 currently valid)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology data indicate that warfarin inhibits vitamin K epoxide reductase (VKORC1), which reduces the vitamin K-dependent clotting factors (II, VII, IX and X). This makes it a standard long-term anticoagulant.

Heparin cofactor II deficiency is an inherited thrombophilia that predisposes patients to thrombosis. Long-term anticoagulation is therefore a plausible way to prevent clots, which is why the model links it to warfarin's existing thrombotic-disease indications.

The graph score likely reflects proximity to thrombotic disease. The available publications are case reports of thrombosis in affected patients, some of whom received warfarin. They do not show that warfarin changes outcomes in this condition.

Other predictions reviewed (none stronger):

Predicted Indication	Score	Evidence Level	Assessment
Factor 5 excess with spontaneous thrombosis	99.84%	L5	No trials or literature; prediction only
Antithrombin deficiency type 2	99.84%	L4	One case report; overlaps with existing thrombotic use
Thrombophilia	99.75%	L3	One Phase 3 trial (status unknown) plus mostly reviews; already standard use, not true repurposing
Rheumatoid arthritis	99.21%	L4	Trials use warfarin only as an interaction probe; no efficacy rationale
Breast fibrocystic disease	99.20%	L5	Score appears to be a danazol-interaction artifact
Benign mammary dysplasia	99.10%	L5	Prediction only; no plausible mechanism

Clinical Trial Evidence

Currently no related clinical trials registered for heparin cofactor 2 deficiency.

For the closest related prediction, thrombophilia, one trial exists:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00895505	Phase 3	Unknown	300	D-dimer-guided duration of oral anticoagulation after unprovoked deep vein thrombosis; tests a duration strategy, no results available

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2214444	1990	Case report	Kyobu Geka	Right ventricular thrombosis in a 14-year-old with familial heparin cofactor II deficiency
2033902	1991	Case report	Nihon Kyobu Shikkan Gakkai Zasshi	Woman with congenital antithrombin deficiency and pulmonary infarction; treated with warfarin for 7 years, then switched to heparin
11570053	2001	Case report (family study)	Journal of UOEH	Family with multiple thromboses, including onset in infancy; warfarin started in one child who later had a recurrence

New Zealand Market Information

All six licences are cancelled, and no approved indication text is available.

Authorization Number	Product Name	Dosage Form	Approved Indication
2586967	Coumadin	Tab 1 mg	Not available (cancelled)
2586975	Coumadin	Tab 2 mg	Not available (cancelled)
2586983	Coumadin	Tab 5 mg	Not available (cancelled)
210587	Marevan	Tab 1 mg	Not available (cancelled)
210595	Marevan	Tab 3 mg	Not available (cancelled)

A sixth licence (210609, Marevan Tab 5 mg) is also cancelled.

Safety Considerations

The package insert warnings and contraindications could not be retrieved, so please refer to the package insert for safety information.

The following comes from drug-disease contraindication links in the knowledge graph, not from label text, and should be verified against the label:

Cardiovascular and metabolic: hypertension, congestive heart failure, hyperlipidemia, hypothyroidism
Liver and biliary: liver failure, liver disease, gallbladder disease, cholestasis
Kidney: impaired renal function, nephrotic syndrome
Blood: blood coagulation disease, anemia
Other: psychotic and mental disorders, substance abuse/dependence, connective tissue and bone disease, chronic diarrheal disease

Drug interaction data: The only entry is the pharmacological target, VKORC1, which is warfarin's mechanism rather than an interaction with another drug. Literature in the data also notes interactions with leflunomide and danazol, and a rare complication, warfarin-induced skin necrosis, which is relevant in protein C/S deficiency.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for heparin cofactor 2 deficiency is limited to three old case reports, with no trials. Warfarin is already used for thrombotic disease, so this is not a distinct repurposing opportunity. Warfarin has no currently valid New Zealand licence, and safety label data are missing.

To proceed, the following is needed:

Medsafe package insert warnings and contraindications
Mechanism of action data from DrugBank
Controlled or cohort data on warfarin in inherited thrombophilias such as heparin cofactor II deficiency
Clarification of why all New Zealand licences were cancelled and whether any warfarin product is currently supplied
Consideration of newer anticoagulants (DOACs) as comparators, as discussed in the 2024 ISTH communication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.